secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2022-11-21T23:59:59+00:00
Accession:  0001193125-22-289920
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir announces resignation of Chief Commercial Officer Jeroen van Beek effective Nov 23
--------------------------------------------------------------------------------

- EVP and CCO Jeroen van Beek resigns Nov 23, 2022 to pursue new opportunities; will consult through Dec 31.
- Company begins search for new head of Commercial organization.
- Separation benefits: lump sum base salary through Dec 31, 2022, 2022 cash bonus, COBRA through Nov 23, 2023, and accelerated vesting of options/RSUs vesting by Dec 31, 2022.
- Separation Agreement includes non-competition, confidentiality, and non-solicitation covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522289920/0001193125-22-289920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522289920/d368771d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-289920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer